KPIs & Operating Metrics(New)
Breakdown Of AssetsCardio MetabolicCardiovascular Revenue Disaggregated AnnualEmployee StatisticsEstablished Brands Revenue Disaggregated AnnualEstablished MedicinesGross Margin By Segment %Gross Margin By Segment Annual %Gross Profit By SegmentGross Profit By Segment AnnualHematologyHematology Revenue Disaggregated AnnualImmunology, Hepatology And DermatologyImmunology Revenue Disaggregated AnnualIncome Before Income TaxInnovative Medicines Revenue By RegionInnovative Medicines Revenue By Region AnnualInnovative Medicines Revenue SegregationInnovative Medicines Revenue Segregation AnnualNeuroscienceNeuroscience Revenue Disaggregated AnnualNon Current Assets By Country AnnualNon Current Assets By Region AnnualNon Ifrs ProfitabilityNon Ifrs Profitability %Non Ifrs Profitability AnnualNon Ifrs Profitability Annual %OncologyOperating Income By SegmentOperating Margin By Segment %Opex As A % Of RevenueOPEX SegregationOphthalmologyOther Promoted Branda Revenue Disaggregated AnnualPipeline ProjectsProperty, Plant And Equipment AnnualRespiratoryRevenue By Country AnnualRevenue By Country Annual %Revenue By GeographyRevenue By Geography %Revenue By RegionRevenue By SegmentRevenue By Segment %Revenue By Segment % Annual %Revenue By Segment AnnualSandoz Net Sales By FranchiseSandoz Revenue By RegionSandoz Revenue By Region AnnualSolid Tumors Revenue Disaggregated Annual
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Innovative Medicines Revenue Segregation (2016 - 2025)